[
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=097a1bd2d4cc83ddc39624ee52e3a949e61b40d9c35c7dd8d66a2bbb7e3c565a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288500,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 136070649,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=097a1bd2d4cc83ddc39624ee52e3a949e61b40d9c35c7dd8d66a2bbb7e3c565a"
    }
  },
  {
    "ts": null,
    "headline": "Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion",
    "summary": "The rheumatoid arthritis therapeutics market, valued at USD 29.50 billion in 2024, is set to grow at a 4.60% CAGR, reaching USD 46.26 billion by 2034. Key drivers include rising RA cases, aging populations, and increased generic drug approvals. Leading companies include Pfizer, Amgen, and Novartis. Rheumatoid Arthritis Therapeutics Market Rheumatoid Arthritis Therapeutics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034\"",
    "url": "https://finnhub.io/api/news?id=85af9737bfa9a97ac80e9972b4e62a22f5afc371fd22ebd67169d5f0feaec313",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753279380,
      "headline": "Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion",
      "id": 136045425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The rheumatoid arthritis therapeutics market, valued at USD 29.50 billion in 2024, is set to grow at a 4.60% CAGR, reaching USD 46.26 billion by 2034. Key drivers include rising RA cases, aging populations, and increased generic drug approvals. Leading companies include Pfizer, Amgen, and Novartis. Rheumatoid Arthritis Therapeutics Market Rheumatoid Arthritis Therapeutics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034\"",
      "url": "https://finnhub.io/api/news?id=85af9737bfa9a97ac80e9972b4e62a22f5afc371fd22ebd67169d5f0feaec313"
    }
  },
  {
    "ts": null,
    "headline": "Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?",
    "summary": "AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.",
    "url": "https://finnhub.io/api/news?id=269ef53d452cc72ad46dd759ed1134393bf4197c408e722f6b54a619e5c5b2da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753278420,
      "headline": "Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?",
      "id": 136045433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.",
      "url": "https://finnhub.io/api/news?id=269ef53d452cc72ad46dd759ed1134393bf4197c408e722f6b54a619e5c5b2da"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's (NASDAQ:AMGN) three-year earnings growth trails the 10% YoY shareholder returns",
    "summary": "Buying a low-cost index fund will get you the average market return. But across the board there are plenty of stocks...",
    "url": "https://finnhub.io/api/news?id=f25e1cbdb03e32eecbfa5aa65194559de9d551b0253f567de74129a008e8c0d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753272025,
      "headline": "Amgen's (NASDAQ:AMGN) three-year earnings growth trails the 10% YoY shareholder returns",
      "id": 136044292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Buying a low-cost index fund will get you the average market return. But across the board there are plenty of stocks...",
      "url": "https://finnhub.io/api/news?id=f25e1cbdb03e32eecbfa5aa65194559de9d551b0253f567de74129a008e8c0d2"
    }
  },
  {
    "ts": null,
    "headline": "Do You Believe in the Growth Potential of Amgen (AMGN)?",
    "summary": "Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. Although the U.S. equity market started with volatility in the second quarter, it rebounded with strength, with the S&P 500 Index rising 10.94% during the quarter. The composite returned 4.88% […]",
    "url": "https://finnhub.io/api/news?id=f4c5eff9c22bc4614022e683a7e89b4585d9d817b1f261df0b9bac2bf1e33f00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753271199,
      "headline": "Do You Believe in the Growth Potential of Amgen (AMGN)?",
      "id": 136044293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. Although the U.S. equity market started with volatility in the second quarter, it rebounded with strength, with the S&P 500 Index rising 10.94% during the quarter. The composite returned 4.88% […]",
      "url": "https://finnhub.io/api/news?id=f4c5eff9c22bc4614022e683a7e89b4585d9d817b1f261df0b9bac2bf1e33f00"
    }
  },
  {
    "ts": null,
    "headline": "Calciphylaxis Market Forecast Report 2025-2034 | Rising Incidence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) Fueling Demand and Growth",
    "summary": "The calciphylaxis market, valued at USD 3.90 Billion in 2024, is projected to reach USD 11.68 Billion by 2034, with a CAGR of 11.59%. Increasing CKD and ESRD cases drive demand. Advances in diagnostics and therapies, such as high-quality imaging and sodium thiosulfate, enhance growth. Key players include Amgen and Smith & Nephew. Calciphylaxis Market Calciphylaxis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Calciphylaxis Market Report and Forecast 2025-2034\" report has been added to Re",
    "url": "https://finnhub.io/api/news?id=76b375e16e8caf54f82629b837989634e808ace903bcc5643cc961f60fc065d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753257840,
      "headline": "Calciphylaxis Market Forecast Report 2025-2034 | Rising Incidence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) Fueling Demand and Growth",
      "id": 136039677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The calciphylaxis market, valued at USD 3.90 Billion in 2024, is projected to reach USD 11.68 Billion by 2034, with a CAGR of 11.59%. Increasing CKD and ESRD cases drive demand. Advances in diagnostics and therapies, such as high-quality imaging and sodium thiosulfate, enhance growth. Key players include Amgen and Smith & Nephew. Calciphylaxis Market Calciphylaxis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Calciphylaxis Market Report and Forecast 2025-2034\" report has been added to Re",
      "url": "https://finnhub.io/api/news?id=76b375e16e8caf54f82629b837989634e808ace903bcc5643cc961f60fc065d0"
    }
  }
]